ADMA Biologics Inc (NAS:ADMA)
$ 24.11 -0.40 (-1.63%) Market Cap: 5.75 Bil Enterprise Value: 5.83 Bil PE Ratio: 29.40 PB Ratio: 16.29 GF Score: 69/100
Back to the Transcripts List

Q4 2024 ADMA Biologics Inc Earnings Call Transcript

Mar 03, 2025 / 09:30PM GMT
Release Date Price: $15.83 (-3.42%)

Key Points

Positve
  • ADMA Biologics Inc (ADMA) reported a significant revenue increase of 65% year-over-year, reaching $426.5 million in 2024.
  • The company achieved a 309% growth in adjusted EBITDA, reaching $164.6 million, showcasing strong operational performance.
  • ADMA Biologics Inc (ADMA) raised its financial guidance, expecting total revenue to exceed $490 million in 2025 and $605 million in 2026.
  • The company has secured long-term third-party plasma supply contracts, increasing its collection capacity fivefold, which supports future growth.
  • ADMA Biologics Inc (ADMA) anticipates a potential mid-year regulatory approval for its enhanced yield production process, which could increase production output by 20%.
Negative
  • The company faces risks and uncertainties related to forward-looking statements, which could impact actual results.
  • There is a growing queue of new patients waiting to start treatment with incentives, indicating potential supply constraints.
  • The company is reliant on regulatory approval for its enhanced yield production process, which is not guaranteed.
  • ADMA Biologics Inc (ADMA) has a net cash surplus but still carries $75 million in total debt, which could impact financial flexibility.
  • The company is experiencing a delay in filing its Form 10K due to the need for additional time to test and document controls, which may raise concerns about internal processes.
Operator

Good afternoon and welcome to the ADMA biologics 4th quarter and full year 2024 financial results and business update conference call on Monday, March 3, 2025. At this time, all participants are in the listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately 2 hours following the end of the call. At this time, I would like to introduce the company. Please go ahead.

Skyler Bloom
ADMA Biologics Inc - Corporate Strategy, Business Development

Welcome everyone, and thank you for joining us this afternoon to discuss ADMA Biologic's financial results for the 4th quarter and full year 2024 in recent corporate updates.

I'm joined today by Adam Grossman, President and Chief Executive Officer, and Brad Tay, Chief Financial Officer and treasurer.

During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and then Brad will provide an overview of the

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.